Healthcare/Biotech Analyst Tejavibulya, along with Reneo Pharmaceuticals’ management and Dr. Robert Pitceathly discuss the expectations for Reneo’s Phase 2b data for mavodelpar (PPARdelta agonist) in primary mitochondrial myopathies (PMM) and its commercial opportunity on an Analyst/Industry conference call to be held on November 9 at 3 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPHM:
- Jefferies healthcare/biotech analysts hold an analyst/industry conference call
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals announces poster presentation on mavodelpar
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
